June 23, 2020 / 8:06 PM / 21 days ago

BRIEF-Medigene Enters Phase I Clinical Development With Its Tcr-T Immunotherapy Mdg1021 In Hematological Cancers

June 23 (Reuters) - Medigene AG:

* PTA-NEWS: MEDIGENE AG: MEDIGENE ENTERS PHASE I CLINICAL DEVELOPMENT WITH ITS TCR-T IMMUNOTHERAPY MDG1021 IN HEMATOLOGICAL CANCERS

* MEDIGENE AG - RECEIVED APPROVAL FROM DUTCH REGULATORY AUTHORITY TO BEGIN FIRST CLINICAL TRIAL OF MDG1021. MDG1021

* MEDIGENE AG - PHASE I CLINICAL TRIAL IN CANCER PATIENTS SUFFERING FROM RELAPSE/PERSISTENCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below